It would only have been possible for start-up Element Zero to deliver an operational green iron prototype in two years with its assumed funding with the help of a “substantial amount of information” on how the project should progress, metals giant Fortescue claims.
Mining company Fortescue, which alleges green iron startup Element Zero misused confidential information, is fighting a bid to cross-examine its external lawyer as part of an application to quash search orders.
Seeking to quash search orders won by metals company Fortescue against former employees who founded a green iron rival, a lawyer for the start-up has said three terabytes of data were indiscriminately copied, including confidential, privileged and irrelevant material.
Metal mining company Fortescue hired private investigators to spy on former employees who created green iron start-up Element Zero, sifting through their mail, taking photos of their children and following them to Kmart, a court has heard.
A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.
Start-up Element Zero claims Fortescue did not disclose material information to the court when it obtained search orders in its case alleging “industrial scale misuse” of the mining company’s confidential information.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company’s confidential information.
Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.
Queensland technology company Anteotech has hit back at a lawsuit claiming it misused Ferroglobe’s confidential silicon samples in a patent application after a failed collaboration, saying the global speciality metals producer acquiesced to the use.
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.